HomeCompareHLUBF vs EPRT

HLUBF vs EPRT: Dividend Comparison 2026

HLUBF yields 3.77% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $44.0K in total portfolio value
10 years
HLUBF
HLUBF
● Live price
3.77%
Share price
$4.82
Annual div
$0.18
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.3K
Annual income
$0.38
Full HLUBF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — HLUBF vs EPRT

📍 EPRT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLUBFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLUBF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLUBF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLUBF
Annual income on $10K today (after 15% tax)
$320.43/yr
After 10yr DRIP, annual income (after tax)
$0.32/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, EPRT beats the other by $11,194.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLUBF + EPRT for your $10,000?

HLUBF: 50%EPRT: 50%
100% EPRT50/50100% HLUBF
Portfolio after 10yr
$42.3K
Annual income
$6,585.62/yr
Blended yield
15.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

HLUBF
No analyst data
Altman Z
2.1
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLUBF buys
0
EPRT buys
0
No recent congressional trades found for HLUBF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLUBFEPRT
Forward yield3.77%3.97%
Annual dividend / share$0.18$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%29%
Portfolio after 10y$20.3K$64.3K
Annual income after 10y$0.38$13,170.85
Total dividends collected$381.00$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: HLUBF vs EPRT ($10,000, DRIP)

YearHLUBF PortfolioHLUBF Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$10,888$188.49$11,212$512.01$324.00EPRT
2$11,747$95.90$12,689$692.09$942.00EPRT
3$12,617$48.35$14,521$944.30$1.9KEPRT
4$13,525$24.27$16,841$1,302.88$3.3KEPRT
5$14,484$12.15$19,841$1,821.64$5.4KEPRT
6$15,503$6.08$23,818$2,587.47$8.3KEPRT
7$16,592$3.04$29,230$3,744.65$12.6KEPRT
8$17,755$1.52$36,816$5,540.38$19.1KEPRT
9$18,998$0.76$47,806$8,413.17$28.8KEPRT
10$20,329$0.38$64,324$13,170.85$44.0KEPRT

HLUBF vs EPRT: Complete Analysis 2026

HLUBFStock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Full HLUBF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this HLUBF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLUBF vs SCHDHLUBF vs JEPIHLUBF vs OHLUBF vs KOHLUBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.